Scientific Advisory Board

Edward Chu, MD, Chair.

Professor of Medicine, Pharmacology & Chemical Biology at the University of Pittsburgh School of Medicine; Chief of the Division of Hematology-Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine; Deputy Director of the University of Pittsburgh Cancer Institute (UPCI); and Leader of the UPCI Molecular Therapeutics and Drug Discovery Program.   Prior to his position at the University of Pittsburgh, Dr. Chu served as Deputy Director of the Yale Cancer Center and the Yale University School of Medicine.

Joseph R. Bertino, MD.

Associate Director at The Cancer Institute of New Jersey and Professor of Medicine & Pharmacology at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School.  Dr. Bertino was formerly Head of the Yale Cancer Center and more recently Chairman of Molecular Pharmacology and Therapeutics Program at the Sloan-Kettering Institute for Cancer Research.

Alec Goldenberg, MD.

Director, Hematology Clinic and Hepatoma Tumor Study Group, Bellevue Hospital, New York University Medical Center; Clinical Associate Professor of Medicine, New York University School of Medicine; and clinical practitioner. Dr. Goldenberg has 20 years combined experience in clinical oncology practice with Memorial Sloan-Kettering and New York University.

Gerard Milano, PharmD.

Head of Oncopharmacology Laboratory & Director of Scientific Affairs, Centre Antoine Lacassagne, Nice, France.  Dr. Milano has held various scientific board positions and is presently on the Lique Nationale Contre le Cancer – PACA in France. He is a world leader in the field of 5-fluorouracil pharmacokinetics and has published more than three hundred studies in peer-review journals.

Leslie M. Shaw, PhD.

Director, Clinical Toxicology Laboratory and Xenobiotic Toxicokinetics Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center; Founder and Chair, Therapeutic Drug and Toxicology Monitoring Scientific Section of the American Society for Clinical Pharmacology and Therapeutics. From 1999 to 2001, he was President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Li Zhang, MD.

Professor of Medical Oncology and Deputy Director of Lung Cancer Research Centre at Sun Yat-Sen University; Chief of the Department of Medical Oncology and Associate Director of the National Anti-Cancer Drug Clinical Research Centre at the Sun Yat-Sen University Cancer Centre in Guangzhou, China. Dr. Zhang also serves on the Board of the International Association for the Study of Lung Cancer, as vice chairman of the Association of Rehabilitation and Palliative Care and vice chairman of both the Cancer Chemotherapy Association and Lung Cancer Association of the Guangdong Province.